Zeltia SA : Zeltia reports first quarter sales of € 31.1 million and Reduces operating costs by 2.5%
04/27/2012| 01:37am US/Eastern
Zeltia reports first quarter sales of € 31.1 million and
Reduces operating costs by 2.5%
Madrid, Spain 26 April 2012: Spain's largest
biotechnology company, Zeltia S.A. (Madrid: ZEL)
("Zeltia" or the "Company"), today
announces its un-audited consolidated results for the quarter
ending 31st March 2012. The report is compiled under
International Financial Reporting Standards (IFRS). The full
report is available at www.zeltia.com.
Net sales of the Zeltia Group ('Zeltia' or the 'Company') for
the first quarter 2012 were €31.3 million (Q1 2011: €35
million). Of the total net sales, 57% were generated by the
biopharmaceutical segment, totalling €17.8 million (Q1
€20.7 million). Of these, €16.4 million are attributed to the
sales of Yondelis (Q1
2011: €19.6 million). Notably, in March last year the Company
recorded income from a delivery of active pharmaceutical
ingredient to Janssen (Johnson & Johnson) of €2.4 million.
Eliminating the effect of this item, commercial sales
4.2% year on year. This was largely due to the ongoing
shortage of Caelyx, which
is used in combination with Yondelis for the treatment of
The net sales of the consumer chemicals segment were €13.3
million (Q1 2011:
€14.5 million). Whilst varnishes and protective wood coatings
saw an increase in sales, other business lines were impacted
by the ongoing consumer slow down in European economies and
particularly in the domestic market.
Focus on operational efficiency across the Group resulted in
a reduction of operating costs by 2.5% during the first
The previously announced focusing of the budget at Noscira on
the ongoing Phase II trial in Alzheimer's disease resulted in
a decrease of 3.6% in R&D investment during the period.
About Zeltia S.A.
Zeltia S.A. is the largest biotechnology company in Spain and
the world leader in marine derived anti- cancer drugs. The
Group's principal activities are to manufacture
bio-pharmaceutical products especially the development of
marine derived anti-cancer drugs and CNS pathologies
treatments. Other activities include developing diagnostics
kits; RNAi technology-based therapeutical applications and
the manufacture and sale of consumer chemicals.
For more information +34 91 444 4500
This note is also available on the Zeltia's website: www.zeltia.com